All patients
age >= 60 yr autoimmune disease invasive ventilation no oxygen needed non invasive oxygen
corticosteroids in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Jamaati, 2021 1.19 [0.38; 3.72]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
1.08 [0.71 ; 1.65 ] Jamaati, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 3 0% 526 serious not evaluable deathsdetailed results CAPE-COVID, 2020 0.45 [0.20; 1.02]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Edalatifard, 2020 0.29 [0.15; 0.56]
Jamaati, 2021 1.19 [0.38; 3.72]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
0.77 [0.55 ; 1.08 ] CAPE-COVID, 2020, CODEX (Tomazini), 2020, DEXA-COVID19, 2020, Edalatifard, 2020, Jamaati, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Steroids-SARI, 2020 8 54% 1,123 moderate not evaluable deaths (time to event analysis only)detailed results Edalatifard, 2020 0.29 [0.15; 0.56]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
0.67 [0.35 ; 1.31 ] Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 3 81% 560 serious not evaluable clinical deteriorationdetailed results CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
0.66 [0.43 ; 1.02 ] CODEX (Tomazini), 2020 1 0% 299 NA not evaluable clinical improvementdetailed results Edalatifard, 2020 12.00 [2.39; 60.20]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
1.81 [0.89 ; 3.70 ] Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 3 72% 600 serious not evaluable clinical improvement (14-day)detailed results REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
1.16 [0.84 ; 1.60 ] REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 2 0% 498 serious not evaluable death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
1.29 [0.59 ; 2.80 ] CAPE-COVID, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 3 67% 365 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
1.67 [0.87 ; 3.19 ] CAPE-COVID, 2020 1 0% 149 NA not evaluable mechanical ventilationdetailed results CAPE-COVID, 2020 0.95 [0.44; 2.04]
Jamaati, 2021 1.38 [0.45; 4.20]
1.07 [0.57 ; 2.01 ] CAPE-COVID, 2020, Jamaati, 2021 2 0% 199 low not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
4.89 [1.15 ; 20.79 ] Jamaati, 2021 1 0% 50 NA not evaluable serious adverse eventsdetailed results CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
Edalatifard, 2020 0.81 [0.11; 6.17]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
1.06 [0.41 ; 2.77 ] CODEX (Tomazini), 2020, Edalatifard, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020 4 17% 841 serious not evaluable superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
0.81 [0.49 ; 1.34 ] CAPE-COVID, 2020 1 0% 149 NA not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 01:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 522,582,666,1149,1150,737,544,733
- roots T: 290
